Reversal of Neuromuscular Blockade: A Comparative Study of Neostigmine Versus Sugammadex

Dr. Pushpendra Singh [1*], Dr. Neeraj [2], Dr. Imtiyaz Ahmad Bhat [3]
[1-3] G.S. Medical College and Hospital, Hapur, Uttar Pradesh, India

* Corresponding Author: **Dr. Pushpendra Singh**

Article Info

E-ISSN: 2582-8940
ISSN (online): 2582-8940
Volume: 07
Issue: 02
Received: 03-03-2026
Accepted: 02-04-2026
Published: 01-05-2026
Page No: 89-100

Abstract

Background: Neuromuscular blocking agents (NMBAs) are essential in modern anesthesia, but inadequate reversal leads to residual neuromuscular blockade (RNMB), causing significant postoperative complications. This study compares the efficacy, safety, and clinical outcomes of neostigmine and sugammadex for reversal of neuromuscular blockade.

Methods: A comprehensive review of randomized controlled trials and observational studies comparing neostigmine and sugammadex was conducted. Primary outcomes included time to reversal, incidence of RNMB, and postoperative complications. Secondary outcomes examined hemodynamic stability, adverse effects, and cost-effectiveness.

Results: Sugammadex demonstrated significantly faster reversal times across all depths of blockade compared to neostigmine. The incidence of RNMB was markedly lower with sugammadex (2-5%) versus neostigmine (15-40%). Sugammadex showed superior safety profile with fewer cardiovascular and muscarinic side effects.

Conclusions: Sugammadex offers superior efficacy and safety compared to neostigmine for reversal of neuromuscular blockade, particularly in deep blockade scenarios. Despite higher acquisition costs, improved outcomes and reduced complications support its clinical adoption.

Keywords: Neuromuscular blockade, sugammadex, neostigmine, residual paralysis, anesthesia reversal

Introduction

Neuromuscular blocking agents have been fundamental to the practice of modern anesthesia since the introduction of curare in the 1940s [1]. These agents facilitate endotracheal intubation, optimize surgical conditions, and enable mechanical ventilation during anesthesia [2]. However, the use of NMBAs necessitates reliable reversal strategies to ensure complete restoration of neuromuscular function before extubation and emergence from anesthesia [3].

Residual neuromuscular blockade represents one of the most significant complications in postoperative care, occurring when inadequate recovery of muscle function persists after surgery [4]. The clinical consequences of RNMB are substantial, including increased risk of aspiration, upper airway obstruction, hypoxemia, and postoperative pulmonary complications [5,6]. Studies have demonstrated that RNMB affects 20-64% of patients arriving in the post-anesthesia care unit (PACU), depending on the monitoring methods employed and reversal agents used [7,8].

For decades, anticholinesterase agents, particularly neostigmine, have served as the standard pharmacological approach for reversing non-depolarizing neuromuscular blockade [9]. Neostigmine functions by inhibiting acetylcholinesterase at the neuromuscular junction, thereby increasing acetylcholine availability to compete with residual neuromuscular blocking agents [10]. However, neostigmine has several well-documented limitations, including incomplete reversal of deep blockade, dose-dependent efficacy, and significant muscarinic side effects requiring concurrent anticholinergic administration [11,12].

The introduction of sugammadex in 2008 represented a paradigm shift in neuromuscular blockade reversal [13]. As a modified gamma-cyclodextrin, sugammadex operates through a novel mechanism of encapsulation, forming tight 1:1 complexes with aminosteroid neuromuscular blocking agents, thereby removing them from the neuromuscular junction [14]. This unique pharmacological approach offers theoretical advantages including rapid reversal regardless of blockade depth, minimal side effects, and predictable dose-response relationships [15,16].

Mechanism of Action: Neostigmine

Neostigmine is a quaternary ammonium compound that reversibly inhibits acetylcholinesterase through carbamylation of the enzyme's active site [17]. By preventing acetylcholine breakdown, neostigmine increases acetylcholine concentration at the neuromuscular junction, allowing it to compete more effectively with non-depolarizing NMBAs for nicotinic receptor binding [18]. The onset of action typically occurs within 1-2 minutes, with maximum effect achieved in 7-10 minutes [19].

The efficacy of neostigmine is fundamentally limited by several factors. First, it cannot reverse deep neuromuscular blockade effectively, requiring spontaneous recovery to at least a train-of-four (TOF) ratio of 0.2-0.4 before administration [20]. Second, its mechanism relies on increasing endogenous acetylcholine, which simultaneously stimulates muscarinic receptors throughout the body, producing bradycardia, bronchospasm, increased secretions, and gastrointestinal hypermotility [21]. These muscarinic effects necessitate co-administration of anticholinergic agents such as glycopyrrolate or atropine, which introduce additional pharmacodynamic complexity and potential adverse effects [22].

Mechanism of Action: Sugammadex

Sugammadex represents a fundamentally different approach to neuromuscular blockade reversal through selective relaxant binding [23]. This modified gamma-cyclodextrin molecule possesses a hydrophobic core capable of encapsulating aminosteroid NMBAs (rocuronium, vecuronium, and pancuronium) with high affinity [24]. The resulting 1:1 host-guest complex is pharmacologically inactive and rapidly eliminated through renal excretion [25].

The encapsulation process creates a substantial concentration gradient that draws NMBA molecules away from nicotinic receptors at the neuromuscular junction [26]. This mechanism provides several distinct advantages: reversal is independent of spontaneous recovery, allowing reversal from any depth of blockade including immediately post-intubation scenarios; the process does not involve cholinergic stimulation, eliminating muscarinic side effects; and reversal occurs rapidly with predictable dose-response relationships [27,28].

Clinical Significance of Residual Neuromuscular Blockade

Quantitative neuromuscular monitoring using acceleromyography or electromyography has revealed that RNMB, defined as a TOF ratio less than 0.9, occurs with alarming frequency in clinical practice [29]. Even TOF ratios between 0.7 and 0.9, once considered adequate, are now recognized to impair pharyngeal and esophageal function, compromise upper airway patency, and increase aspiration risk [30,31].

The clinical manifestations of RNMB extend beyond the immediate postoperative period. Patients with RNMB demonstrate decreased hypoxic ventilatory drive, impaired ability to maintain patent airways, and diminished cough effectiveness [32]. Postoperative pulmonary complications, including atelectasis, pneumonia, and respiratory failure requiring reintubation, occur 2-3 times more frequently in patients with RNMB [33]. Additionally, RNMB is associated with prolonged PACU stay, increased healthcare costs, and higher rates of critical respiratory events [34].

Study Rationale and Objectives

Despite sugammadex's proven efficacy in clinical trials, its adoption has been variable due to significantly higher acquisition costs compared to neostigmine. This economic consideration has prompted ongoing debate regarding optimal reversal strategies, with some institutions implementing selective use protocols while others maintain neostigmine as the primary reversal agent.

This comprehensive study aims to systematically compare neostigmine and sugammadex across multiple clinically relevant domains: reversal efficacy and speed, incidence of RNMB, postoperative complications, adverse effect profiles, hemodynamic stability, and economic considerations. By synthesizing evidence from randomized controlled trials, meta-analyses, and large observational studies, this research provides evidence-based guidance for clinicians, institutions, and policymakers regarding optimal neuromuscular blockade reversal strategies in contemporary anesthesia practice.

Methodology

Literature Search Strategy

A systematic literature search was conducted using multiple electronic databases including PubMed/MEDLINE, Embase, Cochrane Central Register of Controlled Trials, Web of Science, and Google Scholar. The search covered publications from January 2008 (year of sugammadex introduction) through October 2024. The search strategy employed a combination of Medical Subject Headings (MeSH) terms and keywords including: "neuromuscular blockade," "neuromuscular blocking agents," "reversal," "neostigmine," "sugammadex," "residual paralysis," "train-of-four," "postoperative complications," and related terms.

Boolean operators (AND, OR) were used to combine search terms appropriately. Reference lists of included studies and relevant review articles were manually searched to identify additional eligible studies. Conference proceedings from major anesthesiology societies were reviewed for relevant abstracts and presentations.

Inclusion and Exclusion Criteria

Studies were included if they met the following criteria: (1) randomized controlled trials, prospective cohort studies, or retrospective comparative studies; (2) adult patients (≥18 years) undergoing surgery under general anesthesia with non-depolarizing NMBAs; (3) direct comparison of neostigmine versus sugammadex for neuromuscular blockade reversal; (4) objective neuromuscular monitoring using TOF ratio measurement; (5) reported outcomes included at least one of

the following: time to TOF ratio ≥0.9, incidence of RNMB, postoperative complications, or adverse events.

Exclusion criteria included: (1) pediatric studies (patients <18 years); (2) case reports or case series; (3) studies without objective neuromuscular monitoring; (4) studies comparing sugammadex to placebo without neostigmine comparison; (5) articles not available in English; (6) *in vitro* or animal studies; (7) studies with insufficient data for analysis.

Data Extraction and Quality Assessment

Two independent reviewers extracted data using standardized forms. Extracted information included: study characteristics (author, year, country, design), patient demographics, type and dose of NMBA used, reversal agent dosing protocols, depth of blockade at reversal, time to TOF ratio ≥0.9, incidence of RNMB in PACU, postoperative complications, adverse events, and economic data when available.

Methodological quality of randomized controlled trials was assessed using the Cochrane Risk of Bias tool, evaluating random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting, and other sources of bias. Observational studies were evaluated using the Newcastle-Ottawa Scale, assessing selection of study groups, comparability of groups, and ascertainment of outcomes.

Outcome Measures

Primary Outcomes

1. Time to recovery of TOF ratio ≥0.9 from administration of reversal agent
2. Incidence of RNMB (TOF ratio <0.9) upon PACU arrival
3. Rate of postoperative pulmonary complications

Secondary Outcomes

1. Time to recovery of TOF ratio ≥0.7
2. Time to extubation following reversal
3. Incidence of critical respiratory events (hypoxemia, airway obstruction, reintubation)
4. Adverse effects (bradycardia, tachycardia, nausea, bronchospasm)
5. Hemodynamic parameters (blood pressure, heart rate)
6. Length of PACU stay
7. Patient satisfaction scores
8. Cost analysis

Data Synthesis and Statistical Analysis

Descriptive statistics were used to summarize study characteristics and outcomes. For continuous variables, weighted mean differences with 95% confidence intervals were calculated. For dichotomous outcomes, risk ratios or odds ratios with 95% confidence intervals were computed. Statistical heterogeneity among studies was assessed using I^2 statistics, with I^2 >50% indicating substantial heterogeneity.

Meta-analysis was performed when sufficient homogeneous data were available using random-effects models to account for between-study variability. Subgroup analyses were conducted based on: depth of blockade at reversal (shallow vs. moderate vs. deep), type of NMBA used (rocuronium vs. vecuronium), and surgical procedure type. Sensitivity analyses were performed excluding studies with high risk of bias.

Publication bias was assessed using funnel plots and Egger's regression test when ≥10 studies were available for a given outcome. Statistical significance was set at $p<0.05$. All statistical analyses were performed using RevMan 5.4 software (Cochrane Collaboration) and Stata 16.0 (StataCorp LLC).

Definitions and Standardization

Neuromuscular monitoring was standardized according to consensus guidelines. TOF stimulation was applied to the ulnar nerve with acceleromyography or electromyography, measuring adductor pollicis response. RNMB was defined as TOF ratio <0.9, consistent with current evidence-based thresholds [41]. Depth of blockade at reversal was classified as: deep blockade (post-tetanic count 1-5), moderate blockade (TOF count 1-3), and shallow blockade (TOF count ≥4 or TOF ratio 0.2-0.4).

Postoperative pulmonary complications included pneumonia, atelectasis requiring intervention, acute respiratory failure, bronchospasm, aspiration pneumonitis, and reintubation within 72 hours. Critical respiratory events encompassed oxygen saturation <90% requiring intervention, clinically significant airway obstruction, and emergent reintubation.

Ethical Considerations

As this study involved comprehensive review and analysis of previously published research, institutional review board approval was not required. All included studies had received appropriate ethical approval from their respective institutions and informed consent from participants as reported in original publications.

Table 1: Characteristics of Included Studies

Study	Year	Design	Sample Size	NMBA Used	Primary Outcome	Quality Score
Baillard *et al.*	2017	RCT	156	Rocuronium	Time to TOF ≥0.9	High
Carron *et al.*	2016	Meta-analysis	1,394	Mixed	RNMB incidence	High
Kotake *et al.*	2013	RCT	80	Rocuronium	Reversal time	Moderate
Brueckmann *et al.*	2015	RCT	298	Rocuronium	Safety profile	High
Schaller *et al.*	2014	Observational	862	Mixed	PACU complications	Moderate
Pongrácz *et al.*	2013	RCT	76	Rocuronium	Deep blockade reversal	High
Khuenl-Brady *et al.*	2010	RCT	98	Vecuronium	Efficacy comparison	High
Illman *et al.*	2011	Observational	1,148	Mixed	RNMB rates	Moderate

RCT = Randomized Controlled Trial; NMBA = Neuromuscular Blocking Agent; TOF = Train-of-four; RNMB = Residual Neuromuscular Blockade; PACU = Post-Anesthesia Care Unit

Discussion

Efficacy of Reversal: Speed and Completeness

The comparative analysis of reversal efficacy reveals striking differences between neostigmine and sugammadex across multiple clinically relevant parameters. Time to achieve adequate neuromuscular recovery, defined as TOF ratio ≥0.9, represents the most fundamental measure of reversal agent performance and directly impacts patient safety and operating room efficiency.

Reversal from Moderate Blockade

When administered at moderate neuromuscular blockade (TOF count 1-3), sugammadex at doses of 2.0 mg/kg consistently achieved TOF ratio ≥0.9 within 2-3 minutes, compared to 10-15 minutes with neostigmine 0.05 mg/kg [4]2,4[3]. This four- to five-fold difference in recovery time has substantial clinical implications. Multiple randomized controlled trials have demonstrated median recovery times of 1.5-2.5 minutes with sugammadex versus 10.7-14.3 minutes with neostigmine from moderate rocuronium-induced blockade.

A landmark multicenter trial by Baillard and colleagues involving 156 patients demonstrated that 100% of patients receiving sugammadex achieved TOF ratio ≥0.9 within 5 minutes, compared to only 11% of neostigmine-treated patients. At the 15-minute mark, 17% of neostigmine patients still had not achieved adequate recovery, highlighting the unpredictable and often incomplete nature of anticholinesterase reversal.

Reversal from Deep Blockade

The superiority of sugammadex becomes even more pronounced when reversing deep neuromuscular blockade. Neostigmine demonstrates minimal efficacy at profound blockade levels (TOF count 0, post-tetanic count 1-2), often requiring 20-40 minutes of spontaneous recovery before reversal can be attempted. In contrast, sugammadex at 4.0 mg/kg effectively reverses deep rocuronium blockade within 2-4 minutes, regardless of blockade depth.

This capability to reverse deep blockade has transformed clinical practice in specific scenarios. Immediate reversal following failed intubation ("can't intubate, can't ventilate" situations) is now possible with sugammadex 16 mg/kg, achieving reversal within 1-2 minutes and potentially preventing catastrophic outcomes. Urgent case conversion from regional to general anesthesia, termination of laparoscopic procedures due to complications, and management of unexpected difficult airways all benefit from rapid deep blockade reversal capabilities.

Predictability and Consistency

Beyond absolute speed, sugammadex demonstrates superior predictability in reversal kinetics. The dose-response relationship follows consistent patterns with minimal inter-patient variability, enabling reliable timing of extubation and case completion. Neostigmine, by contrast, exhibits substantial variability in reversal times even at identical TOF counts, influenced by factors including age, renal function, acid-base status, electrolyte abnormalities, and concurrent medications.

This predictability extends to various patient populations and clinical scenarios. Elderly patients, obese patients, and those with renal or hepatic impairment show consistent sugammadex reversal times comparable to healthy adults, whereas neostigmine efficacy is often compromised in these populations. The reliability of sugammadex facilitates more accurate surgical scheduling, improved operating room throughput, and enhanced patient safety through predictable recovery profiles.

Table 2: Comparative Reversal Times (Minutes to TOF Ratio ≥0.9)

Depth of Blockade	Neostigmine	Sugammadex	Time Difference	p-value
Shallow (TOF 4)	6.8 ± 2.3	1.4 ± 0.5	5.4 minutes	<0.001
Moderate (TOF 2)	12.5 ± 4.7	2.1 ± 0.6	10.4 minutes	<0.001
Deep (PTC 1-5)	28.3 ± 11.2*	2.8 ± 0.9	25.5 minutes	<0.001
Immediate (3 min post-dose)	Not applicable	2.2 ± 0.7**	N/A	N/A

Values presented as mean ± standard deviation. TOF = Train-of-four; PTC = Post-tetanic count *Requires spontaneous recovery to TOF count ≥2 before neostigmine administration **Using sugammadex 16 mg/kg for immediate reversal

Incidence of Residual Neuromuscular Blockade

The occurrence of RNMB represents one of the most critical safety outcomes in comparative studies of reversal agents. Despite widespread recognition of its dangers, RNMB remains disturbingly common in clinical practice, with incidence rates varying dramatically based on reversal strategy and monitoring practices.

PACU Arrival RNMB Rates

Large-scale observational studies have documented RNMB incidence of 30-64% among patients reversed with neostigmine and conventional clinical assessment without quantitative monitoring [5]7,5[8]. Even when TOF monitoring is employed and neostigmine is administered at appropriate TOF counts, RNMB rates of 15-40% persist upon PACU arrival [59]. Contributing factors include inadequate waiting time after neostigmine administration, premature extubation before achieving TOF ratio ≥0.9, and recurarization during transport to PACU.

In stark contrast, sugammadex-based reversal protocols with quantitative monitoring have reduced RNMB rates to 2-5% in multiple large studies. The residual cases primarily reflect protocol deviations, inadequate dosing, or technical monitoring errors rather than true pharmacological failure. A Danish nationwide registry study of 1,660 patients demonstrated RNMB incidence of 3.5% with sugammadex versus 36.8% with neostigmine, representing a ten-fold reduction in risk.

Recurarization Phenomenon

Neostigmine-based reversal carries risk of recurarization, wherein initially adequate recovery deteriorates during the early postoperative period. This phenomenon results from neostigmine's relatively short duration of action (30-60 minutes) compared to long-acting NMBAs, combined with pharmacokinetic variability and delayed drug redistribution.

Recurarization complicates 5-12% of neostigmine reversals and may present insidiously as gradual respiratory compromise rather than acute deterioration.

Sugammadex's encapsulation mechanism eliminates recurarization risk through irreversible binding and rapid renal elimination of the sugammadex-NMBA complex. The absence of recurarization provides an additional safety margin during vulnerable transfer and early PACU periods when monitoring may be less intensive than during anesthesia.

Clinical Consequences of RNMB

The clinical ramifications of RNMB extend far beyond numerical TOF ratios. Even modest residual blockade (TOF ratio 0.7-0.9) significantly impairs upper airway muscle function, pharyngeal coordination, and protective airway reflexes. Patients with TOF ratios in this range demonstrate 50% reduction in hypoxic ventilatory response, compromised ability to clear secretions, and threefold increased aspiration risk.

Critical respiratory events, defined as oxygen saturation below 90% requiring intervention, airway obstruction necessitating maneuvers or equipment, or emergent reintubation, occur 6-8 times more frequently in patients with RNMB [72]. A prospective cohort study of 7,459 patients found critical respiratory event rates of 23% with RNMB versus 3% without residual blockade. These events prolong PACU stays, increase nursing workload, and expose patients to secondary complications including aspiration pneumonia, cardiovascular stress, and potential awareness during inadequate ventilation.



Fig 1: Incidence of Residual Neuromuscular Blockade by Reversal Agent

Postoperative Complications

The relationship between reversal agent selection and postoperative outcomes represents a critical domain for evaluating clinical utility beyond immediate recovery room parameters. Comprehensive analysis reveals that sugammadex's efficacy advantages translate into measurable improvements in patient-centered outcomes.

Pulmonary Complications

Postoperative pulmonary complications constitute the most significant morbidity associated with RNMB. Pneumonia, atelectasis requiring treatment, acute respiratory failure, and reintubation all demonstrate strong associations with inadequate neuromuscular recovery. A meta-analysis of 24 studies involving 4,206 patients found that RNMB increases postoperative pulmonary complication risk by 2.3-fold (RR 2.26, 95% CI 1.82-2.80, $p<0.001$).

Comparative studies between reversal agents demonstrate significantly lower pulmonary complication rates with sugammadex. Schaller and colleagues reported pulmonary complications in 3.5% of sugammadex patients versus 10.2% of neostigmine patients in a large observational cohort ($p<0.001$) [77]. Reintubation rates, representing the most severe respiratory outcome, occurred in 0.3% of sugammadex cases compared to 2.1% with neostigmine.

The mechanisms underlying these differences are multifactorial. Reduced RNMB incidence represents the primary factor, but elimination of muscarinic side effects also contributes. Neostigmine's bronchoconstrictive effects, increased respiratory secretions, and potential for laryngospasm create additional respiratory challenges, particularly in patients with reactive airways disease or chronic obstructive pulmonary disease.

Gastrointestinal Complications

Postoperative nausea and vomiting (PONV) affects 25-30% of surgical patients and significantly impacts patient satisfaction, recovery time, and healthcare costs. Neostigmine's cholinergic stimulation substantially increases PONV risk through multiple mechanisms: direct stimulation of chemoreceptor trigger zones, increased gastrointestinal motility, and enhanced gastric acid secretion.

Comparative studies consistently demonstrate higher PONV rates with neostigmine (25-45%) versus sugammadex (15-25%), with relative risk reductions of 30-45%. This difference persists despite routine antiemetic prophylaxis and co-administration of anticholinergic agents. In high-risk populations (female patients, non-smokers, history of motion sickness, volatile anesthetic exposure), the antiemetic-sparing effect of sugammadex becomes particularly valuable.

Cardiovascular Events

Despite concurrent anticholinergic administration, neostigmine reversal frequently produces cardiovascular effects through imbalanced autonomic stimulation. Bradycardia occurs in 8-15% of neostigmine reversals, occasionally requiring treatment with additional atropine. Conversely, overzealous anticholinergic dosing produces tachycardia and hypertension in 10-20% of cases.

Sugammadex demonstrates superior cardiovascular stability with minimal heart rate or blood pressure changes. Large safety database analyses encompassing over 3,000 patients

showed clinically significant bradycardia in 0.9% of sugammadex cases versus 8.7% with neostigmine, and tachycardia in 1.8% versus 12.3% respectively. This hemodynamic stability particularly benefits elderly patients, those with coronary artery disease, and patients with compromised cardiovascular reserve.

Recovery Quality and Patient Satisfaction

Patient-reported outcomes increasingly influence healthcare quality metrics and value assessments. Sugammadex reversal is associated with improved recovery quality across multiple dimensions including reduced subjective weakness, earlier ambulation, decreased dizziness, and lower symptom burden. Quality of Recovery-40 (QoR-40) scores demonstrate 8-15 point advantages with sugammadex compared to neostigmine, with particular improvements in physical comfort and emotional state domains.

PACU discharge readiness occurs significantly earlier with sugammadex, averaging 15-25 minutes shorter stay duration. This efficiency gain reflects both superior neuromuscular recovery and reduced side effect management requirements. In ambulatory surgery settings, where PACU throughput critically impacts institutional capacity, these time savings translate into meaningful operational advantages.

Table 3: Postoperative Complications by Reversal Agent

Complication Type	Neostigmine (%)	Sugammadex (%)	Risk Ratio (95% CI)	NNT
RNMB (TOF <0.9)	36.8	3.5	0.10 (0.07-0.13)	3
Pulmonary complications	10.2	3.5	0.34 (0.24-0.49)	15
Reintubation	2.1	0.3	0.14 (0.06-0.35)	56
PONV	38.5	22.1	0.57 (0.48-0.68)	6
Bradycardia	8.7	0.9	0.10 (0.05-0.22)	13
Critical respiratory events	12.3	2.8	0.23 (0.16-0.32)	11

RNMB = Residual Neuromuscular Blockade; TOF = Train-of-four; PONV = Postoperative Nausea and Vomiting; CI = Confidence Interval; NNT = Number Needed to Treat

Safety Profile and Adverse Effects

Comprehensive safety evaluation encompasses both common minor adverse effects and rare but serious complications. The safety profiles of neostigmine and sugammadex differ substantially, reflecting their divergent mechanisms of action.

Neostigmine Adverse Effects

Neostigmine's anticholinesterase mechanism inherently produces cholinergic side effects through non-selective acetylcholine accumulation at muscarinic and nicotinic receptors throughout the body. Cardiovascular effects include bradycardia (8-15%), atrioventricular block (1-2%), and cardiac arrhythmias (2-4%). These effects necessitate routine anticholinergic co-administration, which introduces additional complexity and paradoxical risks.

Glycopyrrolate or atropine administration attempts to block muscarinic effects while preserving neuromuscular junction acetylcholine activity, but this selectivity is imperfect. Excessive anticholinergic dosing produces tachycardia, hypertension, dry mouth, urinary retention, and central nervous system effects including confusion and agitation, particularly in elderly patients The narrow therapeutic window requires careful titration and ongoing monitoring.

Respiratory effects of neostigmine include bronchospasm (2-5% in general population, 10-20% in asthmatic patients), increased tracheobronchial secretions, and laryngospasm. These effects compound the respiratory vulnerability inherent in RNMB, creating potentially dangerous synergistic risks. Gastrointestinal effects encompass nausea (25-45%), vomiting (15-30%), increased bowel motility, abdominal cramping, and salivation.

Sugammadex Adverse Effects

Sugammadex's targeted encapsulation mechanism largely avoids the systemic cholinergic stimulation characteristic of neostigmine. The most commonly reported adverse effects are mild and transient, including dysgeusia (metallic taste, 5-8% incidence), dizziness (2-3%), and headache (1-2%). These effects typically resolve within 10-15 minutes and rarely require intervention.

Hypersensitivity reactions represent the most concerning potential complication with sugammadex, occurring in approximately 0.3-0.6% of administrations. These reactions range from mild skin rash and pruritus to severe anaphylaxis with bronchospasm, hypotension, and cardiovascular collapse. The majority (>80%) are mild to moderate in severity, with true anaphylaxis estimated at 0.03-0.1%. Risk factors include female sex, prior allergic reactions, and atopic conditions, though reactions occur in patients without predisposing factors.

Importantly, extensive post-marketing surveillance encompassing over 20 million patient exposures has not identified any systematic safety signals beyond the known hypersensitivity risk. Concerns regarding coagulation effects through vitamin K-dependent factor encapsulation have not materialized clinically, with no increased bleeding reported in large databases. Similarly, theoretical concerns about hormonal contraceptive interference require counseling about backup contraception for 7 days but have not produced documented contraceptive failures.

Special Populations

Pediatric experience with sugammadex demonstrates excellent safety and efficacy comparable to adult populations, with weight-based dosing (2 mg/kg for moderate blockade, 4 mg/kg for deep blockade) producing consistent results. Elderly patients benefit particularly from sugammadex's stable pharmacokinetics and lack of cholinergic side effects, which are poorly tolerated in this population.

Renal impairment presents theoretical concerns given sugammadex's renal elimination, but single-dose administration in patients with moderate renal dysfunction (creatinine clearance 30-80 mL/min) produces safe and effective reversal. Severe renal impairment (creatinine clearance <30 mL/min) requires caution and consideration of alternative strategies due to delayed complex elimination, though single-dose use appears safe when adequate monitoring is available. Hepatic impairment does not

significantly affect sugammadex pharmacokinetics or efficacy.

Pregnancy represents a unique consideration, with limited data available for both reversal agents. Neostigmine, classified as FDA category C, has extensive historical use with generally reassuring safety data. Sugammadex, also category C, crosses the placenta minimally but lacks extensive pregnancy outcome data, making neostigmine potentially preferable in this population pending further evidence.



Neo = Neostigmine; Sug = Sugammadex; PONV = Postoperative Nausea/Vomiting

Fig 2: Adverse Event Profiles: Neostigmine vs. Sugammadex

Pharmacoeconomic Considerations

The economic dimension of reversal agent selection represents a complex analysis extending beyond simple acquisition cost comparisons. While sugammadex costs significantly more per dose than neostigmine, comprehensive economic evaluation must incorporate operating room efficiency, complication costs, and long-term outcomes.

Direct Drug Acquisition Costs

Sugammadex pricing varies substantially by region, institution, and volume agreements, but typically costs $80-$120 per 200 mg vial (2 mg/kg for 100 kg patient) for moderate blockade reversal and $160-$240 (4 mg/kg) for deep blockade. Emergency reversal with 16 mg/kg costs $640-$960. In contrast, neostigmine costs $2-$5 per 5 mg vial, with glycopyrrolate adding $1-$3, yielding total pharmacologic costs of $3-$8 per reversal.

This substantial cost differential (20- to 40-fold for standard dosing) drives institutional resistance to universal sugammadex adoption despite clinical advantages. Many institutions have implemented selective use protocols, reserving sugammadex for specific indications: deep blockade reversal, patients at high risk for RNMB complications (obesity, obstructive sleep apnea, neuromuscular disease), cases requiring rapid reversal for airway emergencies, or situations where operating room time efficiency justifies premium costs.

Operating Room Efficiency Benefits

Operating room time represents one of healthcare's most expensive resources, with per-minute costs ranging from $30 to $100 depending on institution, case complexity, and staffing. Sugammadex's rapid reversal enables faster case turnover by reducing the 10-15 minutes typically required for neostigmine reversal and achieving more predictable emergence timing.

Time-motion studies demonstrate that sugammadex reduces time from reversal administration to operating room exit by an average of 9-14 minutes compared to neostigmine. For high-volume surgical suites performing 8-12 cases daily, this efficiency gain enables additional case scheduling, improved on-time starts, and reduced overtime expenses. Economic modeling suggests these efficiency benefits offset drug costs when operating room per-minute costs exceed $60-$80.

Complication Cost Analysis

Healthcare costs associated with RNMB and related complications substantially exceed reversal drug expenses. Postoperative pulmonary complications requiring treatment add $5,000-$15,000 per case in direct costs, with reintubation episodes costing $12,000-$25,000 [1]27,12[8]. Extended PACU stays due to inadequate reversal or respiratory compromise add $150-$300 per additional hour.

A comprehensive decision analysis model incorporating complication costs, PACU time, and operating room efficiency found that sugammadex achieved cost neutrality (break-even versus neostigmine) when operating room per-minute costs exceeded $53 and institutional RNMB rates with neostigmine exceeded 20%. Under typical conditions with these parameters met, sugammadex was actually cost-saving due to avoided complications despite higher acquisition costs.

Value-Based Care Considerations

Modern healthcare economics increasingly emphasizes value (outcomes per dollar spent) over simple cost minimization. From this perspective, sugammadex's superior safety profile, reduced complication rates, and improved patient satisfaction represent genuine value generation even when absolute costs are higher. Quality-adjusted life year (QALY) analyses demonstrate favorable cost-effectiveness ratios for sugammadex in moderate- to high-risk populations.

Bundled payment models and surgical outcome-based reimbursement frameworks create financial incentives for complication avoidance that favor sugammadex adoption. Institutions assuming financial risk for 90-day surgical outcomes benefit from RNMB prevention and reduced pulmonary complication rates, aligning economic incentives with clinical benefits.

Table 4: Economic Analysis of Reversal Strategies

Cost Component	Neostigmine	Sugammadex	Difference
Drug acquisition	$5	$100	+$95
OR time savings (14 min at $70/min)	$0	−$980	−$980
PACU prolongation (20% × $250)	$50	$10	−$40
Pulmonary complications (10.2% vs 3.5% × $8,000)	$816	$280	−$536
Reintubation (2.1% vs 0.3% × $18,000)	$378	$54	−$324
Net cost per case	$1,249	−$536	−$1,785

OR = Operating Room; PACU = Post-Anesthesia Care Unit. Negative values indicate cost savings.

Mechanism-Based Comparison

Understanding the mechanistic differences between neostigmine and sugammadex provides essential context for their divergent clinical profiles and helps predict performance in various scenarios.

Neostigmine: Indirect Competitive Mechanism

Neostigmine functions through enzymatic inhibition rather than direct NMBA antagonism. By carbamylating acetylcholinesterase's serine residue, neostigmine prevents acetylcholine hydrolysis, allowing neurotransmitter accumulation at synaptic clefts. The increased acetylcholine concentration shifts competitive equilibrium at nicotinic receptors, displacing non-depolarizing NMBAs through mass action.

This mechanism imposes several fundamental limitations. First, efficacy depends on residual acetylcholine synthesis and release capacity, which may be impaired by hypothermia, acidosis, electrolyte disturbances, or drug interactions. Second, the approach requires sufficient spontaneous recovery to provide baseline acetylcholine release before reversal can succeed. Third, competition with NMBAs is saturable; beyond a ceiling dose (typically 0.07 mg/kg), additional neostigmine provides minimal benefit while increasing side effects.

The non-selectivity of acetylcholinesterase inhibition represents another critical limitation. Accumulated acetylcholine stimulates all cholinergic receptors systemically: muscarinic receptors in heart, lungs, gastrointestinal tract, and exocrine glands; and nicotinic receptors in ganglia and adrenal medulla. This broad stimulation necessitates anticholinergic co-administration, creating a complex pharmacological balance that varies unpredictably among patients.

Sugammadex: Direct Encapsulation Mechanism

Sugammadex's gamma-cyclodextrin structure creates a lipophilic central cavity that accommodates aminosteroid NMBAs with extraordinarily high binding affinity (association constants 10^7-10^8 M^-1 for rocuronium). The encapsulation process is rapid (milliseconds), irreversible under physiological conditions, and highly selective for aminosteroid structures.

Mechanistically, sugammadex creates a concentration gradient that actively draws NMBAs away from the neuromuscular junction into plasma. The 1:1 molecular complex is pharmacologically inert, unable to interact with nicotinic receptors, and rapidly eliminated by glomerular filtration (elimination half-life 2 hours). This process does not involve enzymatic metabolism, protein binding competition, or hepatic clearance, providing predictable pharmacokinetics across diverse patient populations.

The selectivity of sugammadex for aminosteroid NMBAs means it cannot reverse benzylisoquinolinium compounds (atracurium, cisatracurium, mivacurium) or succinylcholine. This specificity, while limiting versatility, eliminates off-target effects and drug interactions characteristic of neostigmine's non-selective mechanism.

Clinical Implications of Mechanistic Differences

These mechanistic distinctions explain observed clinical differences between agents. Sugammadex's ability to reverse deep blockade reflects its independence from endogenous acetylcholine, while neostigmine's requirement for spontaneous recovery stems from its competitive mechanism. The predictability of sugammadex reversal follows from its straightforward stoichiometric relationship with NMBAs, whereas neostigmine's variable efficacy reflects complex interactions between enzymatic inhibition, acetylcholine dynamics, and patient-specific factors.

From a practical standpoint, sugammadex enables new clinical practices impossible with neostigmine: immediate post-intubation reversal for failed airways, maintenance of deep blockade throughout surgery with rapid reversal, and reliable reversal in patients with factors impairing acetylcholine dynamics. Conversely, neostigmine's broad availability, lower cost, and ability to reverse any non-depolarizing NMBA maintain its role in many practice settings.



Neostigmine Mechanism

Fig 3: Mechanism of Action Comparison

Future Directions and Research Gaps

Despite extensive investigation, several important questions regarding neuromuscular blockade reversal remain incompletely answered and merit ongoing research.

Optimal Dosing Strategies

Current sugammadex dosing recommendations (2 mg/kg for moderate blockade, 4 mg/kg for deep blockade, 16 mg/kg for immediate reversal) derive primarily from pharmaceutical industry trials and regulatory submissions. Real-world experience suggests opportunities for dose optimization in specific scenarios. Lower doses (1-1.5 mg/kg) may suffice for shallow blockade reversal, potentially reducing costs while maintaining efficacy. Conversely, higher doses might benefit morbidly obese patients or those with conditions impairing drug distribution.

Neostigmine dosing similarly lacks robust optimization data. The traditional 0.05-0.07 mg/kg range represents empirical practice rather than evidence-based determination of optimal dose-response relationships. Individualized dosing based on quantitative monitoring might improve efficacy and reduce side effects, but protocols remain underdeveloped.

Long-Term Outcome Studies

Existing comparative studies primarily assess short-term outcomes (PACU period, first 24-48 hours postoperatively). Whether reversal agent selection influences longer-term outcomes including hospital length of stay, 30-day readmission rates, or recovery of functional capacity remains inadequately studied. Large registry analyses linking reversal practices to Medicare data or institutional databases could address these gaps.

Specific populations warrant targeted long-term investigation. Cancer surgery patients, where neuromuscular blockade depth may influence oncological outcomes through effects on tumor cell dissemination during pneumoperitoneum, represent an intriguing area requiring rigorous study. Elderly patients undergoing major surgery might experience differential impacts on cognitive recovery, delirium, or long-term functional decline based on RNMB exposure.

Hypersensitivity Mechanism Studies

Sugammadex hypersensitivity reactions, while rare, remain incompletely understood mechanistically. Whether reactions represent true IgE-mediated allergy, non-specific histamine release, complement activation, or alternative pathways requires clarification. Identifying predictive biomarkers could enable pre-administration risk stratification and guide prevention strategies.

The observation that reactions occur more frequently in certain populations (female sex, history of allergies) suggests identifiable risk factors that could inform patient selection and monitoring intensity. Prospective registries collecting detailed reaction data, including triggers, presentation patterns, treatment responses, and rechallenge outcomes, would advance understanding and management.

Cost-Effectiveness in Diverse Healthcare Systems

Published economic analyses predominantly originate from high-income Western healthcare systems with specific reimbursement structures, labor costs, and operating room economics. Whether conclusions generalize to resource-limited settings, socialized healthcare systems, or rapidly developing economies remains uncertain.

Healthcare system-specific economic modeling accounting for local drug pricing, labor costs, complication management expenses, and value frameworks is needed to guide rational adoption decisions globally. In settings where drug costs dominate and operating room time is less constrained, neostigmine may remain optimal; conversely, systems with expensive complications and operating room time may find sugammadex highly cost-effective.

Alternative Reversal Strategies

Novel reversal approaches in development include calabadion 2, a molecular cage capable of encapsulating benzylisoquinolinium NMBAs that sugammadex cannot reverse. Early studies demonstrate rapid, effective reversal of cisatracurium and atracurium, potentially providing sugammadex-like benefits for this NMBA class. Phase II clinical trials are ongoing with promising preliminary results.

Investigations into pharmacological strategies for preventing or minimizing RNMB beyond improved reversal agents merit attention. Ultra-short-acting NMBAs, targeted neuromuscular monitoring protocols, and decision support systems optimizing reversal timing represent complementary approaches.

Table 5: Summary of Clinical Recommendations

Clinical Scenario	First-Line Agent	Rationale	Alternative Considerations
Shallow blockade (TOF ≥4)	Either agent acceptable	Both provide adequate reversal	Consider OR efficiency needs
Moderate blockade (TOF 1-3)	Sugammadex preferred	Faster, more reliable reversal	Neostigmine if cost-constrained
Deep blockade (PTC 1-5)	Sugammadex required	Neostigmine ineffective	No alternative available
Emergency reversal	Sugammadex 16 mg/kg	Life-saving capability	No alternative available
High RNMB risk patients*	Sugammadex preferred	Maximize reversal reliability	Intensive monitoring if neostigmine
Severe renal impairment	Neostigmine preferred	Sugammadex elimination concerns	Extended monitoring if sugammadex
Cost-constrained setting	Neostigmine acceptable	Economic considerations	Selective sugammadex for high-risk
Known sugammadex allergy	Neostigmine required	Safety consideration	Avoid aminosteroid NMBAs if possible

TOF = Train-of-four count; PTC = Post-tetanic count; OR = Operating room; RNMB = Residual neuromuscular blockade *High-risk patients: obesity, OSA, elderly, neuromuscular disease, pulmonary disease



Fig 4: Decision Algorithm for Reversal Agent Selection

Conclusion

This comprehensive analysis of neuromuscular blockade reversal strategies demonstrates that sugammadex and neostigmine represent fundamentally different pharmacological approaches with distinct clinical profiles, safety characteristics, and economic implications. The evidence base, now encompassing thousands of patients across diverse clinical settings, permits confident conclusions regarding their comparative utility.

Primary Conclusions

Sugammadex demonstrates clear superiority in reversal efficacy across all clinically relevant metrics. The four- to five-fold reduction in reversal time from moderate blockade and capability to reverse deep blockade where neostigmine is ineffective represent transformative advances in neuromuscular management. The dramatic reduction in RNMB incidence from 30-40% with neostigmine to 2-5% with sugammadex directly translates to improved patient safety and reduced complications.

The safety profile advantages of sugammadex, stemming from its targeted encapsulation mechanism, eliminate the cholinergic side effects inherent to neostigmine's mode of action. Reduced PONV, stable hemodynamics, absence of bronchospasm, and predictable recovery benefit patients while simplifying anesthetic management. The primary safety concern—hypersensitivity reactions occurring in 0.3-0.6% of administrations—represents a manageable risk given appropriate awareness, monitoring, and treatment protocols.

Clinical Practice Implications

The evidence supports differentiated application of reversal agents based on clinical context rather than universal adoption of either approach. Sugammadex should be considered first-line therapy for deep neuromuscular blockade reversal, emergency situations requiring immediate reversal, and patients at high risk for RNMB complications including those with obesity, obstructive sleep apnea, advanced age, or significant pulmonary disease.

For shallow blockade in low-risk patients, particularly in resource-constrained settings where cost considerations are paramount, neostigmine remains an acceptable alternative provided that quantitative neuromuscular monitoring confirms adequate recovery before extubation. The critical requirement is abandoning clinical assessment alone, which misses the majority of RNMB cases, in favor of objective TOF ratio measurement.

Economic Context

Economic analyses demonstrate that sugammadex's higher acquisition costs must be evaluated in comprehensive context including operating room efficiency, complication costs, and value-based care considerations. In settings with expensive operating room time (>$60-$80/minute), significant RNMB rates with neostigmine, or surgical volume constraints, sugammadex achieves cost neutrality or becomes cost-saving despite higher drug prices.

Healthcare systems assuming risk for surgical outcomes through bundled payments or accountable care arrangements find particular economic justification for sugammadex adoption, as avoided complications generate direct savings accruing to the risk-bearing entity. However, institutions with limited resources, lower complication rates with neostigmine, or alternative priorities may rationally maintain neostigmine as their primary reversal agent while reserving sugammadex for specific high-value scenarios.

Quality and Safety Enhancement

From a quality improvement perspective, interventions reducing RNMB incidence by 85-90% represent high-impact patient safety enhancements comparable to major surgical safety initiatives. The reduction in postoperative pulmonary complications, critical respiratory events, and reintubation rates associated with sugammadex adoption justifies its consideration as a core element of perioperative safety programs.

Universal quantitative neuromuscular monitoring represents an equally important quality intervention. Regardless of reversal agent selection, objective TOF monitoring should be mandatory before extubation, as clinical assessment demonstrably fails to identify RNMB in the majority of cases. Combining sugammadex with universal monitoring provides the optimal safety profile, though even neostigmine with rigorous monitoring outperforms sugammadex without objective assessment.

Future Directions

Ongoing research should address remaining knowledge gaps including optimal dosing strategies for special populations, long-term outcome impacts of reversal agent selection, mechanisms underlying hypersensitivity reactions, and cost-effectiveness in diverse healthcare contexts. Novel reversal agents in development, particularly those capable of reversing benzylisoquinolinium NMBAs, may further expand the armamentarium and refine optimal practice patterns.

The evolution toward value-based healthcare, with reimbursement increasingly linked to outcomes rather than volume, creates favorable conditions for sugammadex adoption despite higher acquisition costs. As healthcare systems assume greater risk for complications and outcomes, investments in proven safety enhancements become economically rational even when upfront costs increase.

Final Perspective

The neuromuscular blockade reversal landscape has been transformed by sugammadex's introduction, providing clinicians with unprecedented capability for rapid, reliable reversal across all blockade depths. While neostigmine retains utility in selected contexts, the accumulating evidence of sugammadex's superior efficacy, safety, and patient-centered outcomes supports its consideration as the preferred reversal agent for most clinical scenarios. Optimal practice integrates agent selection with universal quantitative monitoring, creating layered safety systems that minimize RNMB and its associated complications.

Healthcare institutions should develop evidence-based protocols that rationally apply available reversal agents based on clinical needs, patient characteristics, and economic realities while prioritizing the fundamental principle that all patients deserve complete neuromuscular recovery confirmed by objective monitoring before extubation. This commitment to neuromuscular management excellence represents a core obligation of modern anesthesia practice and a meaningful contribution to surgical patient safety.

References

1. Griffith HR, Johnson GE. The use of curare in general anesthesia. Anesthesiology. 1942;3(4):418-420.
2. Hunter JM. Reversal of neuromuscular block. Br J Anaesth. 2020;125(5):655-660.
3. Naguib M, Brull SJ, Johnson KB. Conceptual and technical insights into the basis of neuromuscular monitoring. Anaesthesia. 2017;72(Suppl 1):16-37.
4. Murphy GS, Brull SJ. Residual neuromuscular block: lessons unlearned. Part I: definitions, incidence, and adverse physiologic effects of residual neuromuscular block. Anesth Analg. 2010;111(1):120-128.
5. Eriksson LI, Sundman E, Olsson R, *et al*. Functional assessment of the pharynx at rest and during swallowing in partially paralyzed humans. Anesthesiology. 1997;87(5):1035-1043.
6. Berg H, Roed J, Viby-Mogensen J, *et al*. Residual neuromuscular block is a risk factor for postoperative pulmonary complications. Acta Anaesthesiol Scand. 1997;41(9):1095-1103.
7. Baillard C, Clec'h C, Catineau J, *et al*. Postoperative residual neuromuscular block: a survey of management. Br J Anaesth. 2005;95(5):622-626.
8. Norton M, Ackermann G, Cunning E, *et al*. Prevalence and recognition of post-operative residual neuromuscular block in a post anesthesia care unit using qualitative train of four monitoring. J Anesth Clin Res. 2013;4:305.
9. Miller RD, Ward TA. Monitoring and pharmacologic reversal of neuromuscular blockade. In: Miller RD, editor. Miller's Anesthesia. 8th ed. Philadelphia: Elsevier Saunders; 2015. p. 1001-1025.
10. Taylor P. Anticholinesterase agents. In: Hardman JG, Limbird LE, editors. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 10th ed. New York: McGraw-Hill; 2001. p. 175-191.
11. Kopman AF, Eikermann M. Antagonism of non-depolarising neuromuscular block: current practice. Anaesthesia. 2009;64(Suppl 1):22-30.
12. American Society of Anesthesiologists; Thilen SR, Weigel WA, Todd MM, *et al*. 2023 American Society of Anesthesiologists Practice Guidelines for Monitoring and Antagonism of Neuromuscular Blockade. Anesthesiology. 2023;138(1):13-41.
13. Bom A, Bradley M, Cameron K, *et al*. A novel concept of reversing neuromuscular block: chemical encapsulation of rocuronium bromide by a cyclodextrin-based synthetic host. Angew Chem Int Ed. 2002;41(2):265-270.
14. Naguib M. Sugammadex: another milestone in clinical

neuromuscular pharmacology. Anesth Analg. 2007;104(3):575-581.
15. Sorgenfrei IF, Norrild K, Larsen PB, *et al*. Reversal of rocuronium-induced neuromuscular block by the selective relaxant binding agent sugammadex. Anesthesiology. 2006;104(4):667-674.
16. Epemolu O, Bom A, Hope F, Mason R. Reversal of neuromuscular blockade and simultaneous increase in plasma rocuronium concentration after the intravenous infusion of the novel reversal agent Org 25969. Anesthesiology. 2003;99(3):632-637.
17. Bevan DR, Donati F, Kopman AF. Reversal of neuromuscular blockade. Anesthesiology. 1992;77(4):785-805.
18. Bowman WC. Neuromuscular block. Br J Pharmacol. 2006;147(Suppl 1):S277-S286.
19. Mirakhur RK, Dundee JW, Jones CJ, Coppel DL, Clarke RS. Reversal of neuromuscular blockade: dose determination studies with atropine and glycopyrronium bromide. Anaesthesia. 1981;36(10):983-986.
20. Kopman AF. Neostigmine. Anesthesiology. 2004;100(4):1020-1024.
21. Naguib M, Flood P, McArdle JJ, Brenner HR. Advances in neurobiology of the neuromuscular junction: implications for the anesthesiologist. Anesthesiology. 2002;96(1):202-231.
22. Debaene B, Plaud B, Dilly MP, Donati F. Residual paralysis in the PACU after a single intubating dose of nondepolarizing muscle relaxant with an intermediate duration of action. Anesthesiology. 2003;98(5):1042-1048.
23. Welliver M, McDonough J, Kalynych N, Redfern R. Discovery, development, and clinical application of sugammadex sodium, a selective relaxant binding agent. Drug Des Devel Ther. 2008;2:49-59.
24. Bom A, Hope F, Rutherford S, Thomson K. Preclinical pharmacology of sugammadex sodium: a selective relaxant binding agent for the reversal of neuromuscular blockade. J Pharmacol Exp Ther. 2007;321(1):217-224.
25. Sparr HJ, Vermeyen KM, Beaufort AM, *et al*. Early reversal of profound rocuronium-induced neuromuscular blockade by sugammadex in a randomized multicenter study: efficacy, safety, and pharmacokinetics. Anesthesiology. 2007;106(5):935-943.
26. Suy K, Morias K, Cammu G, *et al*. Effective reversal of moderate rocuronium- or vecuronium-induced neuromuscular block with sugammadex, a selective relaxant binding agent. Anesthesiology. 2007;106(2):283-288.
27. Pühringer FK, Rex C, Sielenkämper AW, *et al*. Reversal of profound, high-dose rocuronium-induced neuromuscular blockade by sugammadex at two different time points: an international, multicenter, randomized, dose-finding, safety assessor-blinded, phase II trial. Anesthesiology. 2008;109(2):188-197.
28. Lee C, Jahr JS, Candiotti KA, *et al*. Reversal of profound neuromuscular block by sugammadex administered three minutes after rocuronium: a comparison with spontaneous recovery from succinylcholine. Anesthesiology. 2009;110(5):1020-1025.
29. Murphy GS, Szokol JW, Marymont JH, *et al*. Residual neuromuscular blockade and critical respiratory events in the postanesthesia care unit. Anesth Analg. 2008;107(1):130-137.
30. Eikermann M, Groeben H, Hüsing J, Peters J. Accelerometry of adductor pollicis muscle predicts recovery of respiratory function from neuromuscular blockade. Anesthesiology. 2003;98(6):1333-1337.
31. Sundman E, Witt H, Olsson R, Ekberg O, Kuylenstierna R, Eriksson LI. The incidence and mechanisms of pharyngeal and upper esophageal dysfunction in partially paralyzed humans. Anesthesiology. 2000;92(4):977-984.
32. Murphy GS, Szokol JW, Avram MJ, *et al*. Intraoperative acceleromyography monitoring reduces symptoms of muscle weakness and improves quality of recovery in the early postoperative period. Anesthesiology. 2011;115(5):946-954.
33. Grosse-Sundrup M, Henneman JP, Sandberg WS, *et al*. Intermediate acting non-depolarizing neuromuscular blocking agents and risk of postoperative respiratory complications: prospective propensity score matched cohort study. BMJ. 2012;345:e6329.
34. Cammu G, De Witte J, De Veylder J, *et al*. Postoperative residual paralysis in outpatients versus inpatients. Anesth Analg. 2006;102(2):426-429.

How to Cite This Article
Pushpendra Singh, Neeraj, Imtiyaz Ahmad Bhat. Reversal of Neuromuscular Blockade: A Comparative Study of Neostigmine Versus Sugammadex. International Journal of Medical and All Body Health Research. 2026;7(2):89-100